OncoGenex Pharmaceuticals (OGXI) shares have plunged in early trading today after the company announced that its Phase 3 clinical trial, AFFINITY, evaluating its lead product candidate custirsen, in combination with cabazitaxel/prednisone, for the treatment of metastatic castration-resistant prostate cancer that has progressed after treatment with docetaxel failed to achieve its primary endpoint of a statistically valid improvement in overall survival (OS) compared to cabazitaxel/prednisone alone. The company plans to contact the FDA to discuss its options for an early analysis of the Phase 3 ENSPIRIT study assessing custirsen, in combination with docetaxel, for the second-line treatment of patients with non-small cell lung cancer.